source
- Attovia Therapeutics raises $289 million in IPO to fund anti-itch drug developmentAttovia Therapeutics completed an initial public offering that generated $289 million in gross proceeds. The company sold 17 million shares at $17 each, exceeding its original target of $182.4 mill…
- Gilead reports modest sales rise but analysts question future growth beyond HIV drugsGilead's second‑quarter results showed total product revenue of $7.6 billion, up 8% year‑over‑year. The company's two leading HIV treatments, Biktarvy and Descovy, together generated about $5.7 bi…